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Background: Several studies have been focused on design and synthesis of multi-target anti Alzheimer
compounds. Utilizing of the dual Acetylcholinesterase/Butyrylcholinesterase inhibitors has gained more interest to
treat the Alzheimer’s disease. As a part of a research program to find a novel drug for treating Alzheimer disease,
we have previously reported 6-alkoxybenzofuranone derivatives as potent acetylcholinesterase inhibitors. In
continuation of our work, we would like to report the synthesis of 5,6-dimethoxy benzofuranone derivatives
bearing a benzyl pyridinium moiety as dual Acetylcholinesterase/Butyrylcholinesterase inhibitors.
Methods: The synthesis of target compounds was carried out using a conventional method. Bayer-Villiger oxidation
of 3,4-dimethoxybenzaldehyde furnished 3,4-dimethoxyphenol. The reaction of 3,4-dimethoxyphenol with
chloroacetonitrile followed by treatment with HCl solution and then ring closure yielded the 5,6-dimethoxy
benzofuranone. Condensation of the later compound with pyridine-4-carboxaldehyde and subsequent reaction
with different benzyl halides afforded target compounds. The biological activity was measured using standard
Ellman’s method. Docking studies were performed to get better insight into interaction of compounds with
receptor.
Results: The in vitro anti acetylcholinesterase/butyrylcholinesterase activity of compounds revealed that, all of the
target compounds have good inhibitory activity against both Acetylcholinesterase/Butyrylcholinesterase enzymes in
which compound 5b (IC50 = 52 ± 6.38nM) was the most active compound against acetylcholinesterase. The same
binding mode and interactions were observed for the reference drug donepezil and compound 5b in docking
study.
Conclusions: In this study, we presented a new series of benzofuranone-based derivatives having pyridinium
moiety as potent dual acting Acetylcholinesterase/Butyrylcholinesterase inhibitors.* Correspondence: aforoumadi@yahoo.com
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Alzheimer’s disease (AD) is a progressive and age-
dependent neurodegenerative brain disorder that leads to
dementia, cognitive impairment, and memory loss [1,2].
The main cause of Alzheimer’s disease etiology is not
completely known however, many diverse factors such as
hippocampal acetylcholine (Ach) decrease, β-amyloid (Aβ)
aggregation and τ-protein deposits seem to play significant
roles in initiation and progression of the disease [3-5].
Based on these findings three hypotheses was established:
cholinergic, β-amyloid and tau hypothesis.
Regarding cholinergic hypothesis one of the most useful
approaches for improving AD’s symptoms is to design
new agents that raise the acetylcholine in the cholinergic
system [6]. Acetylcholinesterase (AChE) is responsible for
hydrolysis of acetylcholine in the synaptic cleft, therefore;
employing the AChE inhibitors could be a helpful strategy
to increase the level of acetylcholine in the damaged cho-
linergic neurons [7]. Several compounds have been previ-
ously synthesized as AChE inhibitors and successfully
used to treat AD, such as Donepezil, Galantamine and
Rivastigmine (Figure 1) [8].
Moreover, it has been demonstrated that the inhibition
of AChE may lead to an increase in Butyrylcholinesterase
(BuChE) activity in the hippocampus that causes hydroly-
sis of AChE by a new way. Therefore, the maintenance of
AChE/BuChE activity ratio in the hippocampus as seen in
the healthy brain, could improve the signs and symptoms
of AD [9]. As a result, design and synthesis of dual AChE/
BuChE inhibitors should be considered to find more po-
tent agents against AD [10].Figure 1 Donepezil, Rivastigmine and Galantamine three well-
known AChE inhibitors.In an earlier report, we have presented the preparation
and evaluation of some new (Z)-1-benzyl-4-((6-alkoxy-3-
oxobenzofuran-2(3H)-ylidene) methyl)pyridinium (Figure 2)
as AChE inhibitors [11]. Most of these compounds proved
to be potent AChE inhibitors in vitro, among which
compounds bearing methoxy group on position 6 of
benzofuran ring showed the most activity. Furthermore, it
was reported that 5,6-dimethoxy benzofuranone structure
is important to show more affinity toward the enzyme
in some aurone-based AChE inhibitors [12,13]. Following
these reasons and in pursuit of our previous study a
series of new 5,6-dimethoxy benzofuran derivatives were
designed, synthesized and evaluated for AChE/BuChE in-
hibitory activities. In this study, we decided to investigate
the possible increase in the enzyme inhibitory activity by re-
placing the less hydrophilic 6-alkoxy benzofuranone scaf-
fold with a more polar 5,6-dimethoxy benzofuranone motif.
The final compounds have been tested for their ability to
inhibit both AChE and BuChE using Ellman’s method [14].Materials and methods
Chemistry
All chemicals were obtained from Merck AG, Aldrich and
Acros Chemicals. Thin layer chromatography (TLC) was
carried out on Merck pre-coated silica gel F254 plates with
various mobile phase systems, to check reaction progress
and product mixtures. The Separating column chromatog-
raphy and flash chromatography were done with silica gel
(70-230 mesh). The 1H nuclear magnetic resonance (NMR)
spectra were recorded in DMSO-d6 and/or CDCl3 on a
Bruker FT-500 MHz spectrometer with tetramethylsilane
(TMS) as the internal standard. Coupling constants were
reported in Hertz (Hz) and chemical shifts are given as δ
value (ppm) relative to TMS as internal standard. To ex-
press spin multiplicities, s (singlet), d (doublet), t (triplet), q
(quartet), dd (double doublet) and m (multiplet) were used.
Mass spectra were obtained at 70 eV in a Finigan TSQ-70
spectrometer. Infrared (IR) spectra were determined usingFigure 2 Previously reported (Z)-1-benzyl-4-((6-alkoxy-3-
oxobenzofuran-2(3H)-ylidene) methyl)pyridinium derivatives as
potent inhibitors of AChE.
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points were determined using Kofler hot stage apparatus
and are uncorrected.Elemental microanalyses were done on
a Perkin–Elmer 240-C apparatus for C, H, and N. For bet-
ter understanding of spectral data, the general structure
and atom numbering of final compounds are depicted in
Figure 3.
Synthesis of 3,4-dimethoxyphenol (1)
A mixture of m-chloro-peroxybenzoic acid (m-CPBA)
(7 g, 32.5 mmol) in the dry dichloromethane (DCM)
(40 ml) was prepared at 0°C and vigorously stirred. Then a
solution of 3,4-dimethoxybenzaldehyde (5 g, 30 mmol) in
the dry DCM (10 ml) was added dropwise during 1 hour.
The resulting mixture was kept at room temperature and
then refluxed for 16 hours. After cooling, the mixture was
washed with aqueous solution of saturated sodium hydro-
gen carbonate (3 × 20 ml) followed by washing with
sodium thiosulfate 10% (25 ml) to neutralize excess
amount of m-CPBA. The solvent was then evaporated
under reduced pressure and the resulting crude material
was dissolved in methanol. The solution was stirred for 4 -
hours with excess amount of sodium hydroxide 10% solu-
tion at room temperature. The pH of solution was adjusted
to 1 using HCl 6 N solution. The solution was then
extracted with DCM (3 × 25 ml) washed with brine and
dried using anhydrous Na2SO4. The solvent was removed
to yield brown syrup, which was purified with column
chromatography using petroleum ether and ethyl acetate
(1:1) as eluent to give compound 1. White brown solid, m.
p. 74–78°C, 84% yield [15].
Synthesis of 2-chloro-1-(2-hydroxy-4,5-dimethoxyphenyl)
ethanone (2)
To a mixture of 3,4-dimethoxyphenol (1) (4.93 g, 32 mmol)
and chloroacetonitrile (2.4 g, 32 mmol) in dry ether
(150 ml) was added anhydrous ZnCl2 (1.44 g, 10.6 mmol).
The mixture was cooled to 0°C and HCl gas was bubbledFigure 3 General structure and atom numbering of
final compounds.through the reaction for 2.5 hours. The mixture was left in
the room temperature overnight and then cooled to 0°C.
The precipitated iminium was filtered off and washed
three times with ether. The imine was dissolved in 160 ml
of 1 N HCl and refluxed for 90 min. The resulting mixture
was extracted with DCM (3 × 100 ml) and the solvent was
removed under reduced pressure to give 2.88 g white
brown solid 40% yield (no further purification was needed).Synthesis of 5,6-dimethoxybenzofuran-3(2H)-one (3)
The crude extract of 2-chloro-1-(2-hydroxy-4,5-dime-
thoxyphenyl)ethanone (2) (1.15 g, 5 mmol) was dissolved
in 10 ml ethanol and then refluxed for 10 min under
argon. Sodium acetate trihydrate (700 mg) was added
thereto and refluxed for 10 min again. The resulting mix-
ture was cooled immediately and then filtered off. The
solvent was evaporated and compound 3 was yielded by
re-crystallization from ethanol. White needle crystals, m.p.
163–165, 470 mg, 48%. IR νmax/cm
-1 (KBr) : 1708 (C =O),
1H NMR (CDCl3, 80 MHz), 7.02 (s, 1H, H4-aromatic) 6.59
(s, 1H, H7-aromatic) 4.61 (s, 2H, H2-aliphatic) 3.97 (s, 3H, -
OCH3) 3.87 (s, 3H, -OCH3), EI-MS m/z (%) 194 (M
+,
100), 165 (45), 135 (88), 34 (57).Synthesis of (Z)-5,6-dimethoxy-2-(pyridin-4-ylmethylene)
benzofuran-3(2H)-one (4)
5,6-dimethoxybenzofuran-3(2H)-one 3 (388 mg, 2 mmol),
pyridine-4-carbaldehyde (308 mg, 2.88 mmol) and PTSA
(548 mg, 3.18 mmol) were suspended in the dry toluene
(25 ml) and refluxed using Dean-Stark apparatus for 2 -
hours. After cooling the resulting mixture, the precipitated
solid was filtered off. The wet solid was suspended in aque-
ous 10% NaHCO3 solution (50 ml) and stirred for 60 -
minutes at room temperature. The filtered resulting solid
was washed with water (50 ml) and then air dried. The
crude solid was purified by re-crystallization from
acetonitrile to yield compound 4. 400 mg, 70% yield, m.p.
265–268°C, IR νmax/cm
-1 (KBr) : 1705 (C =O), 1635 (C =C
alkene), 1H NMR (CDCl3, 80 MHz), 8.69 (dd, 2H, Ha-pyridine,
J= 4.5 Hz, J= 2 Hz), 7.70 (dd, 2H, Hb-pyridine, J= 5 Hz, J=
1.5 Hz), 7.17 (s, 1H, H4), 6.83 (s, 1H, H7), 6.69 (s, 1H,
Hvinylic), 4.03 (s, 3H, -OCH3), 3.91 (s, 3H, -OCH3), EI-MS
m/z (%) 284 ( (M+ + 1), 100), 224 (90), 33 (65).
General procedure for the synthesis of 1-benzyl-4-((5,6-
dimethoxy-3-oxobenzofuran-2(3H)-ylidene)methyl)
pyridinium halide derivatives (5a-g)
(Z)-5,6-Dimethoxy-2-(pyridin-4-ylmethylene) benzofuran-
3(2H)-one (4) (1 equiv.), was suspended in 7 ml dry aceto-
nitrile and heated under reflux condition. Afterwards dif-
ferent substituted benzyl halides (1.2 equiv.) were added
thereto. The mixture was refluxed for 2–3 hours followed
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was evaporated and 15 ml n-hexane was added to the resi-
due. The resulting mixture was filtered off and the
precipitated crystals were separated, washed with n-
hexane and dried. Flash chromatography of the crystals
using the chloroform-methanol (99–1) as the mobile
phase, furnished the final compounds 5a-g.(Z)-1-Benzyl-4-((5,6-dimethoxy-3-oxobenzofuran-2(3H)-
ylidene) methyl) pyridinium bromide (5a)
Starting from (Z)-5,6-dimethoxy-2-(pyridin-4-ylmethylene)
benzofuran-3(2H)-one (1 mmol, 0.283 g) and benzyl brom-
ide (1.2 mmol, 0.205 g), compound 5a was obtained,
quantitative yield, mp over 300°C, IR νmax/cm
-1 (KBr) :
1689 (C =O), 1607 (C =C alkene), 1H NMR (DMSO-d6,
500 MHz), 9.20 (d, 2H, Ha-Pyridine, J = 6.7 Hz), 8.51 (d, 2H,
Hb-pyridine, J = 6.7 Hz), 7.55-7.46 (m, 5H, Hphenyl), 7.27 (s,
1H, H4-benzofuranone), 7.25 (s, 1H, H7-benzofuranone), 7.04 (s,
1H, Hvinylic), 5.85 (s, 2H, Hbenzylic), 3.98 (s, 3H, -OCH3),
3.83(s, 3H, -OCH3), EI-MS m/z (%) 283 (10), 91 (100), 77
(15), 43 (38), Anal. Calcd.for C23H20BrNO4: C, 60.81; H,
4.44; N, 3.08 Found: C, 60.68; H, 4.72; N, 3.24.(Z)-1-(4-Fluorobenzyl)-4-((5,6-dimethoxy-3-oxobenzofuran-2
(3H)-ylidene) methyl) pyridinium bromide (5b)
Starting from (Z)-5,6-dimethoxy-2-(pyridin-4-ylmethylene)
benzofuran-3(2H)-one (1 mmol, 0.283 g) and 4-fluoro-ben-
zyl bromide (1.2 mmol, 0.226 g), compound 5b was
obtained, quantitative yield, mp 276–279°C, IR νmax/
cm-1 (KBr) : 1687 (C = O), 1608 (C = C alkene), 1H
NMR (DMSO-d6, 500 MHz), 9.22 (d, 2H, Ha-pyridine, J =
6.7 Hz), 8.52 (d, 2H, Hb-pyridine, J = 6.75 Hz), 7.67-7.64
(m, 2H, Hphenyl), 7.32-7.28 (m, 2H, Hphenyl), 7.25 (s, 1H,
H4-benzofuranone), 7.23 (s, 1H, H7-benzofuranone), 7.04 (s,
1H, Hvinylic), 5.86 (s, 2H, Hbenzylic), 3.97 (s, 3H, -OCH3),
3.82(s, 3H, -OCH3), EI-MS m/z (%) 283 (12), 109 (100),
95 (18), 43 (40), Anal. Calcd.for C23H19BrFNO4: C,
58.49; H, 4.05; N, 2.97 Found: C, 58.85; H, 4.17; N, 2.74.(Z)-1-(3-Methylbenzyl)-4-((5,6-dimethoxy-3-oxobenzofuran-2
(3H)-ylidene) methyl) pyridinium chloride (5c)
Starting from (Z)-5,6-dimethoxy-2-(pyridin-4-ylmethylene)
benzofuran-3(2H)-one (1 mmol, 0.283 g) and 3-methyl-
benzyl chloride (1.2 mmol, 0.169 g), compound 5c was
obtained, quantitative yield, mp 293–295°C, IR νmax/cm
-1
(KBr) : 1694 (C =O), 1605 (C =C alkene), 1H NMR
(DMSO-d6, 500 MHz), 9.25 (d, 2H, Ha-pyridine, J = 6.4 Hz),
8.51 (d, 2H, Hb-pyridine, J = 6.45 Hz), 7.48-7.41 (m, 3H,
Hphenyl), 7.33 (s, 1H, Hphenyl), 7.26 (s, 1H, H4-benzofuranone),
7.24 (s, 1H, H7-benzofuranone), 7.03 (s, 1H, Hvinylic), 5.83 (s,
2H, Hbenzylic), 3.94 (s, 3H, –OCH3), 3.80 (s, 3H, –OCH3),
2.3 (s, 3H, H –CH3phenyl), EI-MS m/z (%) 283 (12), 105(100), 91 (16), 43 (38), Anal. Calcd.for C24H22ClNO4: C,
68.00; H, 5.23; N, 3.30 Found: C, 68.34; H, 5.05; N, 3.42.
(Z)-1-(2-Fluorobenzyl)-4-((5,6-dimethoxy-3-oxobenzofuran-2
(3H)-ylidene) methyl) pyridinium chloride (5d)
Starting from (Z)-5,6-dimethoxy-2-(pyridin-4-ylmethylene)
benzofuran-3(2H)-one (1 mmol, 0.283 g) and 2-
fluorobenzyl chloride (1.2 mmol, 0.173 g), compound 5d
was obtained, quantitative yield, mp over 300°C, IR νmax/
cm-1 (KBr) : 1701 (C =O), 1608 (C =C alkene), 1H NMR
(DMSO-d6, 500 MHz), 9.19 (d, 2H, Ha-pyridine, J = 5.8 Hz),
8.53 (d, 2H, Hb-pyridine, J = 5.95 Hz), 7.65-7.62 (m, 1H,
Hphenyl), 7.54-7.52 (m, 1H, Hphenyl), 7.34-7.31 (m, 2H,
Hphenyl), 7.26 (s, 1H, H4-benzofuranone), 7.23 (s, 1H, H7-
benzofuranone), 7.05 (s, 1H, Hvinylic), 5.94 (s, 2H, Hbenzylic), 3.95
(s, 3H, –OCH3), 3.80 (s, 3H, –OCH3), EI-MS m/z (%) 283
(16), 109 (100), 95 (18), 43 (35), Anal. Calcd.for
C24H22ClNO4: C, 68.00; H, 5.23; N, 3.30 Found: C, 68.12;
H, 5.32; N, 3.37.
(Z)-1-(3-Fluorobenzyl)-4-((5,6-dimethoxy-3-oxobenzofuran-2
(3H)-ylidene) methyl) pyridinium chloride (5e)
Starting from (Z)-5,6-dimethoxy-2-(pyridin-4-ylmethylene)
benzofuran-3(2H)-one (1 mmol, 0.283 g) and 3-
fluorobenzyl chloride (1.2 mmol, 0.173 g), compound 5e
was obtained, quantitative yield, mp 291–294°C, IR νmax/
cm-1 (KBr) : 1690 (C =O), 1611 (C =C alkene), 1H NMR
(DMSO-d6, 500 MHz), 9.29 (d, 2H, Ha-pyridine, J = 6 Hz),
8.52 (d, 2H, Hb-pyridine, J = 6.2 Hz), 7.51-7.50 (m, 2H,
Hphenyl), 7.43-7.41 (m, 1H, Hphenyl), 7.30-7.27 (m, 1H,
Hphenyl), 7.26 (s, 1H, H4-benzofuranone), 7.23 (s, 1H, H7-
benzofuranone), 7.04 (s, 1H, Hvinylic), 5.9 (s, 2H, Hbenzylic), 3.95
(s, 3H, –OCH3), 3.8 (s, 3H, –OCH3), EI-MS m/z (%) EI-MS
m/z (%) 283 (19), 109 (100), 95 (15), 43 (32), Anal.Calcd.for
C23H19ClFNO4: C, 64.57; H, 4.48; N, 3.27 Found: C, 64.72;
H, 4.23; N, 3.16.
(Z)-1-(2-Methylbenzyl)-4-((5,6-dimethoxy-3-oxobenzofuran-2
(3H)-ylidene) methyl) pyridinium chloride (5f)
Starting from (Z)-5,6-dimethoxy-2-(pyridin-4-ylmethylene)
benzofuran-3(2H)-one (1 mmol, 0.283 g) and 2-methyl-
benzyl chloride (1.2 mmol, 0.169 g), compound 5f was
obtained, quantitative yield, mp 287–290°C, IR νmax/cm
-1
(KBr) : 1692 (C =O), 1607(C =C alkene), 1H NMR
(DMSO-d6, 500 MHz), 9.08 (d, 2H, Ha-pyridine, J = 6.85 Hz),
8.52 (d, 2H, Hb-pyridine, J = 6.8 Hz), 7.81- 7.78 (m, 1H,
Hphenyl), 7.45-7.38 (m, 1H, Hphenyl), 7.32-7.30 (m, 2H,
Hphenyl), 7.29 (s, 1H, H4-benzofuranone), 7.24 (s, 1H, H7-
benzofuranone), 6.99 (s, 1H, Hvinylic), 5.88 (s, 2H, Hbenzylic), 3.99
(s, 3H, –OCH3), 3.84 (s, 3H, –OCH3), 2.35 (s, 3H, H
CH3phenyl) EI-MS m/z (%) 283 (21), 105 (100), 91 (18), 43
(40), Anal. Calcd.for C24H22ClNO4: C, 68.00; H, 5.23; N,
3.30 Found: C, 68.26; H, 5.15; N, 3.25.
Scheme 1 Synthetic routes to final compounds 5a-g (a) m-CPBA, CH2Cl2, reflux 16 hrs; (b) NaOH 10%, r.t., stir., 4 hrs; (c) HCl 6 N; (d)
ClCH2CN, HCl gas, ZnCl2, 0°C, 2.5 hrs, stir.; (e) HCl 1 N, reflux, 90 min; (f) Sodium acetate trihydrate, ethanol, reflux, 10 min; (g)
Pyridine-4-carboxaldehyde, PTSA, toluene, reflux; (h) Substituted benzyl halide, CH3CN, reflux.
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(3H)-ylidene) methyl) pyridinium chloride (5g)
Starting from (Z)-5,6-dimethoxy-2-(pyridin-4-ylmethylene)
benzofuran-3(2H)-one (1mmol, 0.283 g) and 4-methylbenzyl
chloride (1.2 mmol, 0.169 g), compound 5g was obtained,
quantitative yield, mp 294–297°C, IR νmax/cm
-1 (KBr) : 1690
(C =O), 1606 (C =C alkene), 1H NMR (DMSO-d6,
500 MHz), 9.24 (d, 2H, Ha-pyridine, J = 6.4 Hz), 8.49 (d, 2H,
Hb-pyridine, J = 6.5 Hz), 7.47 (d, 2H, J = 6.3 Hz, Hphenyl), 7.26
(d, 2H, J = 6.4 Hz, Hphenyl), 7.20 (s, 1H, H4-benzofuranone), 7.17
(s, 1H, H7-benzofuranone), 6.96 (s, 1H, Hvinylic), 5.80 (s, 2H,
Hbenzylic), 3.95 (s, 3H, –OCH3), 380 (s, 3H, –OCH3), 2.28 (s,
3H, H –CH3phenyl), EI-MS m/z (%) 283 (17), 105 (100), 91
(22), 43 (31), Anal. Calcd.for C24H22ClNO4: C, 68.00; H,
5.23; N, 3.30 Found: C, 67.76; H, 5.38; N, 3.19.
Biological activity
AChE (AChE, E.C. 3.1.1.7, Type V-S, lyophilized powder,
from electric eel, 1000 unit), Cholinesterase from equine
serum were purchased from Sigma–Aldrich (Steinheim,
Germany). DTNB (5, 50-Dithiobis-(2-nitrobenzoic acid)),
KH2PO4, K2HPO4, KOH, NaHCO3, BTChI (butyrylthio-
choline iodide) and ATChI (acetylthiocholine iodide)
were obtained from Fluka (Buchs, Switzerland). To af-
ford an assay concentration range (10-4 to 10-9 M), the
tested compounds were dissolved in a mixture of 20 ml
distilled water and 5 ml methanol followed by dilutionin 0.1 M KH2PO4/K2HPO4 buffer (pH 8.0) to obtain final
concentration.
The colorimetric Ellman’s method was applied to
evaluate anti AChE/BuChE activity of tested compounds.
The solutions temperature was adjusted to 25°C prior to
use. Five different concentrations of each compound
were tested to obtain 20% to 80% inhibition of AChE
and/or BuChE activity. The assay medium contained
3 ml of 0.1 M phosphate buffer pH 8.0, 100 μl of 0.01 M
5, 50-dithio-bis(2-nitrobenzoic acid), 100 μl of 2.5 unit/
mL enzyme solution (AChE, E.C. 3.1.1.7, Type V-S,
lyophilized powder, from electric eel or BuChE from
equine serum).
Then 100 μl of each tested compounds, were added to
the assay medium and pre-incubated at 25°C for 15 min
followed by adding 20 μl of substrate (acetylthiocholine
iodide or butyrylthiocholine iodide). After that the
rate of absorbance change was measured at 412 nm for
2 minutes. The blank reading solution was used to jus-
tify non-enzymatic hydrolysis of substrate during the
assay. The blank solution contained 3 ml buffer, 200 μl
water, 100 μl DTNB and 20 μl substrate. As a reference,
an identical solution of the enzyme without the inhibitor
is processed following the same protocol. The rate of the
substrate enzymatic hydrolysis was calculated, and %
inhibition of the tested compounds was calculated.
Each concentration was evaluated in triplicate, and the
Table 1 AChE/BuChE inhibitory activity of compounds 5a-g compared with Donepezil hydrochloride (IC50 =Mean ± SD)
Compounds R AChE (IC50 ± SD)
a
(nM)





5a H 86 ± 10.94 1400 ± 85 16.27
5b 2-F 52 ± 6.38 1620 ± 73 31.15
5c 3-F 115 ± 15.56 740 ± 23 6.43
5d 4-F 74 ± 11.32 960 ± 41 12.97
5e 2-CH3 262 ± 27.49 3620 ± 84 13.81
5f 3-CH3 208 ± 31.72 5310 ± 115 25.52
5g 4-CH3 514 ± 29.53 7600 ± 260 14.78
Donepezil hydrochloride - 31 ± 5.12 5400 ± 95 174.19
a Data are means ± standard deviation of three independent experiments.
b Selectivity Index (S.I): IC50 BuChE/ IC50 AChE.
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(% of inhibition versus log inhibitor’s concentration)
graphically. Kapková et al. reported more details of the
procedure [16,17].Docking study
Docking simulation studies were done using Autodock Vina
1.1.1 [18]. For this purpose, the pdb structure
of acetylcholinesterase (1EVE) was retrieved from theFigure 4 The superposition of the docked Donepezil (blue) and
reference Donepezil (red) into the active site of the AChE.Brookhaven protein database (RCSB)(http://www.rcsb.org)
as a complex bound with inhibitor Donepezil. Subsequently,
all water molecules and the co-crystallized ligand were
removed from the pdb structure. Afterward the polar
hydrogens were added to the receptor and pdbqt format of
the receptor was created using Autodock Tools 1.5.4 [19].
The ligand coordinates were generated using Marvine-
Sketch 5.8.3, 2012, ChemAxon (http://www.chemaxon.
com). Then the structures were converted to pdbqt using
Open babel 2.3.1 [20]. The docking site was defined by
establishing a box at geometrical center of the native ligand
present in the above mentioned PDB structure with the
dimensions of 40, 40, and 40. The exhaustiveness parameter
was set to 80 and the box center was set to the dimensions
of x = 2.023, y = 63.295, z = 67.062. Finally, the lowest energy
conformations between the AChE and inhibitor were
selected for analyzing the interactions. The results were
visualized using Chimera 1.6 [21].Results and discussion
Chemistry
The target compounds (5a-g) were synthesized as illus-
trated in Scheme 1. The convenient Baeyer–Villiger
oxidation of 3,4-dimethoxybenzaldehyde furnished 3,4-
dimethoxyphenol (1) in a good yield [15]. Reaction of 3,4-
dimethoxyphenol (1) with chloroacetonitrile using ZnCl2
as Lewis acid yielded 2-chloro-1-(2-hydroxy-4,5-dime-
thoxyphenyl)ethane iminium as a key intermediate.
Figure 5 The superposition of best docked poses of all target
compounds (colored by element) as well as Donepezil (green)
into the gorge of AChE.
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ethanone (2) was prepared followed by treatment
of iminium intermediate using hydrochloric acid. Intermo-
lecular cyclization of compound (2) using sodium acetate
resulted in formation of 5,6-dimethoxy-benzofuran-3(2H)-
one (3) [22]. Condensation of 5,6-dimethoxybenzofuran-3
(2H)-one (3) with 4-formyl pyridine in the presence of
PTSA gave (Z)-5,6-dimethoxy-2-(pyridin-4-ylmethylene)
benzofuran-3(2H)-one (4). As previously reported, the
configuration of exocyclic formed double bond was
assigned as Z (cis) isomer [11]. Appropriate benzylFigure 6 The interacting mode of the most active compound 5b withchloride or bromide derivatives were refluxed with com-
pound (4) in dry acetonitrile to obtain final compounds
(5a-g).
Biological activity
The new series of 5,6-dimethoxybenzofuranone derivatives
bearing the benzyl pyridinium moiety was evaluated for
AChE/BuChE activity using slightly modified Ellman’s
protocol.
The type and position of substituents on benzyl moiety
could alter the electronic and steric properties of the phenyl
ring. Therefore, the affinity of the target compounds toward
the enzyme could be modified by changing the substituent
on benzyl moiety.
The anti AChE/BuChE activity data of the target
compounds were summarized in Table 1.
According to the data, all of the synthesized compounds
have shown considerable anti AChE/BuChE activity how-
ever, did not reach the inhibition level of the reference
compound (Donepezil hydrochloride IC50 = 31 ± 5.12 nM).
As already shown in our previous study, the substitution
on phenyl ring with small electron withdrawing group such
as fluorine atom makes the compounds more active rather
than their unsubstituted counterparts. In an opposite way
the methyl phenyl substituted compounds proved to be less
active than the unsubstituted compounds. In this study
using the identical substitution on the ring, the anti
cholinesterase activity of 5,6-dimethoxy-benzofuranone
derivatives has changed in the same way. Regardless of
the substitution on phenyl ring, the activity of morethe active site of AChE.
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slightly diminished, compared to 6-alkoxy benzofuranone
derivatives that were previously reported [11].
As anticipated, the compound 5b (IC50 = 52 ± 6.38
nM) containing 2-F substituent exhibited the highest
inhibitory activity toward the enzyme. However, its activ-
ity was less than its counterparts bearing 6-methoxy
(IC50 = 10 ± 6.87 nM), 6-ethoxy (IC50 = 32 ± 7.75 nM)
and 6-propoxy (IC50 = 50 ± 9.86) on benzofuranone.
Similarly, the 3 and 4-flouro phenyl compounds have
shown lower activity in respect to corresponding 6-alkoxy
benzofuranone series.
According to Table 1, changing the ortho position of
fluorine to either meta or para decreased the activity as
in compound (5c) with significantly diminished activity
(IC50 = 115 ± 15.56).
Accordingly, methyl substituted compounds have
exhibited the order of activity as follow: 5f > 5e > 5g. In-
sertion of methyl group on phenyl ring in any position
reduced the activity in comparison with unsubstituted
compound (5a).
In an accord to these findings, it was concluded that
substitution on position 3 with F and position 4 with –
CH3 was not tolerated.
Docking simulation study
In order to investigate the binding mode for interaction
of the target compounds with AChE, docking studies
were performed. First the co-crystallized ligand was
docked back into the binding site of the enzyme and
superposed with the native ligand (Figure 4).
Being satisfied with the reasonable RMSD between the
docked and native ligands (RMSD = 0.78 Å), the docking
protocol was verified for further docking studies of the tar-
get compounds. The best docked poses of the synthesized
compounds on the target were superposed and showed to
be similarly docked in the gorge of AChE. As shown in
Figure 5, this pattern of orientation resembled very much
to that observed for donepezil.
In order to figure out the binding mode for interaction
of the compounds, the most active compound (5b) was
subjected to further analysis. As depicted in Figure 6, the
5,6-dimethoxybenzofuranone fragment of the ligand was
well accommodated in the PAS (Peripheral Anionic Site)
through a π−π stacking of the phenyl ring of benzofu-
ranone and indole moiety of Trp279. This interaction was
reinforced by a hydrogen bonding between the 6-methoxy
of 5b and the hydroxyl group of Tyr70. In addition, the
benzyl pyridinium part of the ligand was oriented towards
the anionic site (AS) composed by Phe330, Trp84 and
Glu199. The interactions responsible for stabilization of
bezyl pyridinium in the active site included two π−π
stacking and a π-cation interaction. The π-cation inter-
action was formed between Phe330 and the quaternarynitrogen of pyridine ring. Regarding the two π−π
interactions, one was between 2-flouro substituted phenyl
ring and Trp84 and the other between pyridine ring and
Phe330. The same binding mode and interactions were
also observed for the reference drug (Donepzil) [23].
Conclusions
In this study, we presented new benzofuranone-based
derivatives of the pyridinium type. The inhibitory activity
of new synthesized compounds were tested toward AChE
using slightly modified Ellman’s method and compared to
those of other derivatives of this class synthesized earlier
by our research group. Regarding the biological data, it
was revealed that all tested compounds inhibited the
AChE in nanomolar range concentration, in which com-
pound 5b, was the most potent compound against AChE.
Furthermore a same binding mode and interactions was
observed for the reference drug Donepzil and compound
5b in docking study.
In conclusion, 5,6-dimethoxybenzofurane derivatives
containing methylbenzyl substituent on pyridine ring
demonstrated to be more potent than their corresponding
6-ethoxy and 6-propoxy benzofuranone derivatives [11].
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